ToolGen (KOSDAQ)
ToolGen (Республика Корея) разрабатывает технологии редактирования генома для терапии человека, а также для растений и животных.
Профиль
ToolGen (KOSDAQ: 199800) is a South Korean gene-editing company founded in 1999 (Oct 8) that focuses on CRISPR-Cas9 genome editing in eukaryotic cells, built for patent monetization/licensing and development of therapies and gene-edited crop/seed products. Core technology is its optimized CRISPR-Cas9 platform (and foundational IP); its platform is used for therapeutics and crop trait improvement. Headquarters: 8F, 172 Magokjungang-ro, Gangseo-gu, Seoul; R&D center in Osong, Cheongju. Latest 2025-2026 developments: it opened an advanced Osong genome-edited crop field testing facility in June 2026 to accelerate commercialization (SAF and industrial crop focus) and is actively operating; Aug 2026 it announced a strategic partnership with DNA Harvest Partners for AI-guided predictive breeding of rapeseed. Scale (from latest report): 2025 revenue 1,306,445 (KRW million) with license income 1,052,318 (80.5%); patent monetization contributes >80% of sales. Key partners/customers mentioned: Monsanto/Bayer (licensing), and contracts with Monsanto, KeyGene, Thermo Fisher Scientific. Investors/funding and employee/capacity figures are not provided in the supplied results.
Sources#
- 툴젠
- 사 업 보 고 서 — 2026-03-19
- Platform
- ToolGen Opens Advanced Field Testing Facility in Osong, Completing ‘Bench-to-Field’ Commercialization Platform for Global SAF and Industrial Crop Markets — 2026-06-11
- Notice/News — 2026-08-06
- About Us
- Crops
- ToolGen aims to leverage financial strength in global gene-editing IP battle < The interview < ENGLISH NEWS < 기사본문 - 더바이오 — 2026-06-01
- Отрасль
- Энергетика, Семена и генетика
- Темы
- ГМ-признаки и редактирование генома
- Роль
- Не определена
Биорешения, которые поставляет 0
Пока не указана поставщиком в решениях с доказательствами.
Что предлагают
Компания не публикует продукты и услуги — узнаем через знакомство.
Новости и статус 6
- 2026-09 Последний статус: Компания провела размещение прав и привлекла около 19,46 млрд вон на патентные споры и НИОКР; новые акции поступают в обращение 12 октября 2026 г. ↗ ↗ ↗
- 2026-09-03 ToolGen Incorporated Accelerates Development of Gene Therapy for Cardiovascular Diseases… “To File for U.S. Clinical Trials Next Year” - EDAILYToolGen is advancing TGT-002, a gene-editing therapy for lowering Lp(a) to treat ASCVD, and has begun GLP toxicity testing in preclinical development in collaboration with GenEditBio, aiming to file an IND with the FDA in 2027. The company cites progress in …
- 2026-09-29 ToolGen Completes 19.4 Billion Won Rights Offering: “Funds Will Go to Patent Litigation, Not New Drug Development” | Biobook MediaToolGen recently completed a 19.4 billion won rights offering, with the proceeds earmarked mainly for defending its foundational CRISPR-Cas9 patents through litigation rather than funding new drug R&D. This reflects a company whose value and survival are seen …
- 2026-10-01 ToolGen raises millions to fund cost of crucial CRISPR IP battles - IAMToolGen aims to become the “Qualcomm of gene editing” and is funding ongoing CRISPR IP disputes, with several key legal battles expected over the next two years that could determine its strategic position.
- 2026-06-11 ToolGen Opens Advanced Field Testing Facility in Osong, Completing 'Bench-to-Field' Commercialization Platform for Global SAF and Industrial Crop MarketsToolGen has opened an advanced field-testing facility in Osong to accelerate commercializing genome-edited crops for global SAF and industrial crop markets, establishing a full “bench-to-field” platform and an integrated vertical value chain focusing on …
- 2026-05-15 ToolGen Announces 70 Billion Won Capital Increase to Secure Funds for Patent Litigation and R&D - The Asia Business DailyToolGen plans an approximately 70 billion won paid-in capital increase (about 8.6% of its shares) via a shareholder allocation and public offering of forfeited shares to fund patent litigation and R&D, including CRISPR interference with the Broad Institute and …
- 2026-04-16 FDA Eases Uncertainty in Gene Therapy Regulations... Green Light for Korean Companies Like Toolgen to Enter Global Markets - The Asia Business DailyToolGen is positioned to advance U.S. clinical trials for its CRISPR-Cas9 tech (for Charcot–Marie–Tooth disease type 1A) by leveraging new FDA draft safety guidelines for customized gene therapies, which clarify off-target risk assessment and non-clinical data …
Связи: владельцы, партнёры, аналоги
Владельцы и инвесторы 2
| инвестор | Genexine |
| инвестор | Jin-soo Kim |
Партнёры и сделки 1
| сотрудничество | SAF …on (SAF and industrial crop focus) and is actively operating; Aug 2026 it announced a strategic partnership with DNA Harvest Partners for AI-guided predictive breeding of rapeseed. Scale (from… |
Похожие компании
Setsuro Tech Inc. · Soy-Sky FarmTech Company Limited · Shriram Bioseed Genetics (A Division of DCM Shriram Ltd) · AgriGenome Labs Pvt Ltd · KingAgroot CropScience 清原作物科学 · META HELIX LIFE SCIENCES PRIVATE LIMITED · KRYSP-R / GENE2GO · C4U Corporation
Реквизиты и контакты
Контакты, руководители и юридические данные доступны участникам.
Войти как участник